ACLX - Arcellx, Inc.
About Arcellx, Inc. (https://arcellx.com)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Rami Elghandour | Chairman of the Board, Chief Executive Officer & President | 1979 | $1,383,771 USD |
| Michelle Lim Gilson | Chief Financial Officer | 1993 | $878,017 USD |
| Christopher R. Heery | Chief Medical Officer | 1981 | $794,520 USD |
| Neeraj Teotia | Chief Commercial Officer | 1975 | $461,949 USD |
| Aileen Fernandes | Chief Operating Officer | – | – |
| Heba Nowyhed | Chief Scientific Officer | – | – |
| Helen Kim | VP & Head of Regulatory Affairs | – | – |
| Kate Aiken | Chief People Officer | – | – |
| Maryam Abdul-Kareem | General Counsel & Chief Legal Officer | – | – |
| Myesha Lacy | Chief Investor & Communications Officer | – | – |
| Narinderjeet Singh | Chief Technical Officer | 1972 | – |